Name: Topiramate
Brand: Selleck Chemicals
SKU: S1438
Availability: InStock
Rating: 5 (6 reviews)

Jump to

Quality Control

Batch: Purity: >97%

Cited in Nature Medicine for its top-tier quality
COA
NMR
Datasheet
SDS

Cited in Nature Medicine for its top-tier quality
COA
NMR
Datasheet
SDS

Cited in Nature Medicine for its top-tier quality
COA
NMR
Datasheet
SDS

Cited in Nature Medicine for its top-tier quality
COA
NMR
Datasheet
SDS

Cited in Nature Medicine for its top-tier quality
COA
NMR
Datasheet
SDS

97

Related Targets	Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism
Other Carbonic Anhydrase Inhibitors	U-104 Indisulam (E7070) Benzenesulfonamide Tioxolone 2-Aminobenzenesulfonamide

Solubility

In vitro
Batch:

DMSO : 68 mg/mL (200.37 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 68 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	10.000mg/ml (29.47mM)	Taking the 1 mL working solution as an example, add 50 μL of 200 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (14.73mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	339.36	Formula	C₁₂H₂₁NO₈S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	97240-79-4	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	MCN 4853, RWJ 17021			Smiles	CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C

Mechanism of Action

Targets/IC₅₀/Ki	sodium channel Calcium Channel AMPA/kainate receptor Carbonic anhydrase
In vitro	Topiramate slightly inhibits the persistent fraction of Na+ current in dissociated neurons and reduces the Na+-dependent long-lasting action potential shoulders, which can be evoked in layer V pyramidal neurons after Ca+ and K+ current blockade in neocortical slices. This compound at low concentrations (IC50, approximately 0.5 mM) selectively inhibits pharmacologically isolated excitatory synaptic currents mediated by kainate receptors containing the GluR5 subunit in whole-cell voltage-clamp recordings from principal neurons of the rat basolateral amygdala. It also partially depresses predominantly AMPA-receptor-mediated EPSCs, but with lower efficacy. This chemical suppresses voltage-sensitive Na+ channels and non-N-methyl-D-aspartate (NMDA) receptors and enhances gamma-aminobutyric acid (GABA)-mediated inhibition. It selectively inhibits postsynaptic responses mediated by GluR5 kainate receptors.
In vivo	Topiramate (25-100 mg/kg, i.p.) produces a dose-dependent elevation in the threshold for clonic seizures induced by infusion of ATPA, a selective agonist of GluR5 kainate receptors. This compound effectively suppresses acute seizures induced by perinatalhypoxia in a dose-related manner with a calculated ED50 of 2.1 mg/kg, i.p. It (20 and 40 mg/kg i.p.) inhibits both tonic and absence-like seizures in a dose-dependent manner, whereas Phenytoin (20 mg/kg i.p.) and Zonisamide (40 mg/kg i.p.) inhibits only the tonic seizures. This chemical inhibits sound-induced seizures in DBA/2 mice (ED50 = 8.6 mg/kg p.o.).
References	[1] https://pubmed.ncbi.nlm.nih.gov/10027832/ [2] https://pubmed.ncbi.nlm.nih.gov/12904467/ [3] https://pubmed.ncbi.nlm.nih.gov/9757028/ [4] https://pubmed.ncbi.nlm.nih.gov/15111016/ [5] https://pubmed.ncbi.nlm.nih.gov/11558793/ [6] https://pubmed.ncbi.nlm.nih.gov/8206119/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06282783	Not yet recruiting	HIV-1-infection\|Hiv\|HIV Infections\|HIV I Infection	Erasmus Medical Center	September 2024	Phase 1\|Phase 2
NCT05975580	Recruiting	Obesity	University of California Irvine\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	August 29 2023	Phase 4
NCT04613024	Not yet recruiting	Weight Loss\|Pain Postoperative	Stanford University	July 1 2023	Early Phase 1
NCT04986631	Recruiting	Obesity Childhood	University of Minnesota	April 4 2022	Early Phase 1
NCT03308669	Completed	Healthy	Eli Lilly and Company	October 16 2017	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Topiramate Carbonic Anhydrase inhibitor

Chemical Structure

Molecular Weight: 339.36